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Abstract
Background: The aim of the study was to assess a panel of promising biomarkers for their ability to improve
diagnosis of sporadic amyotrophic lateral sclerosis (ALS).
Methods: Forty patients with sporadic ALS and 40 controls with other neurological diseases were evaluated. Levels
of phosphorylated neurofilament heavy chain (pNfH), S100-β, cystatin C, and chitotriosidase (CHIT) in cerebrospinal
fluid were assayed using two-site solid-phase sandwich ELISA.
Results: Patients with sporadic ALS showed higher levels of pNfH and CHIT than controls, but lower levels of
cystatin C. Multivariate logistic regression that adjusted for patient age and sex identified significant associations
between sporadic ALS and levels of pNfH, CHIT and cystatin C. Levels of pNfH correlated positively with rate of
progression and decline based on the Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised. Based on
receiver operating curve analysis, a pNfH cut-off of 437 ng/L discriminated patients from controls with a sensitivity
of 97.3 % and specificity of 83.8 %. A CHIT cut-off of 1593.779 ng/L discriminated patients from controls with a
sensitivity of 83.8 % and specificity of 81.1 %. Combining the two biomarkers gave a sensitivity of 83.8 % and
specificity of 91.9 %.
Conclusions: Levels of pNfH in cerebrospinal fluid may be a reliable biomarker for diagnosing ALS, and combining
this biomarker with levels of CHIT may improve diagnostic accuracy.
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Background
Amyotrophic lateral sclerosis is a fatal neurodegenerative
disorder. It is diagnosed based on purely on clinical
evaluation and differential diagnosis to exclude other
possible conditions, highlighting the need to identify ob-
jective biomarkers that may aid diagnosis and perhaps
help predict progression and prognosis.
Several candidate ALS biomarkers have been identified
in cerebrospinal fluid (CSF), including neurofilament
proteins, S100-β, cystatin C, and chitotriosidase (CHIT)
[1, 2]. The validity of these biomarkers remains contro-
versial, since they were identified using targeted
approaches rather than unbiased screens and they have
been assessed individually in separate studies, rather
than in parallel. In addition, studies have not assessed
the diagnostic potential of combinations of these candi-
date biomarkers.
Here we examined several candidate ALS biomarkers:
phosphorylated neurofilament heavy chain (pNfH),
S100-β, cystatin C, and CHIT. Our objective was to
identify, in parallel comparisons, which biomarker(s)
may be the most effective, as well as assess the diagnos-
tic potential of biomarker combinations.
Methods
Patients and samples
This study involved 40 patients clinically diagnosed with
definite or probable sporadic ALS between May 2006 and
November 2013 in the Department of Neurology at West
China Hospital, Sichuan University (Chengdu, China). We
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also recruited 40 age- and sex- matched control patients
diagnosed with non-ALS neurological diseases. These
controls had lower motor neuron disease (n = 21), includ-
ing spinal muscular atrophy (n = 8), multifocal motor
neuropathy with conduction block (n = 6), spinal and
bulbar muscular atrophy (n = 4), and chronic inflam-
matory demyelinating neuropathy (n = 3); or upper
motor neuron disease (n = 19), including cervical myel-
opathy (n = 9), multiple sclerosis (n = 7), and hereditary
spastic paraparesis (n = 3).
Motor and functional status of patients with sporadic
ALS was quantified by neurologists using the Amyo-
trophic Lateral Sclerosis Functional Rating Scale - Revised
(ALSFRS-R). ‘Progression rate’ was calculated from
the equation: [(48 −ALSFRS-R score at baseline evalu-
ation)/disease duration in months from symptom on-
set to evaluation]. Annual decline in ALSFRS-R was
calculated from the equation: [(value at baseline examin-
ation − value at last examination)/years between the two
examinations]. Monthly decline in ALSFRS-R was calcu-
lated by dividing the annual decline in ALSFRS-R by 12.
CSF samples were obtained from all study participants
by lumbar puncture. Samples were centrifuged at
3000 rpm for 10 min at 4 °C to remove particulate
matter. Protease inhibitor cocktail was added, and sam-
ples were aliquoted and stored at −80 °C until analysis.
ELISA
Commercial two-site solid-phase sandwich ELISAs
were used to assay levels of pNfH (RD191138300R,
Biovendor), S100-β (RD192090100R, Biovendor), cysta-
tin C (RD191009100, Biovendor) and CHIT (cy-8074,
MBL) in CSF samples. Kits were used according to the
manufacturers’ instructions. Before definitive measure-
ments were taken, we assessed the stability of all four
biomarkers in CSF by assaying their levels in samples that
had been collected less than 30 min previously or more
than 24 h previously and then stored at different tem-
peratures. Biomarker levels remained stable after stor-
age at −80 °C. Biomarkers did not appreciably
aggregate under sample storage and thawing condi-
tions, based on recovery experiments in which known
amounts of biomarkers were added to the sample.
Statistical analysis
Data were reported as mean ± standard deviation or
median (range) and analyzed using SPSS 17.0 (IBM,
Chicago, IL, USA). Since most data showed a skewed
distribution, intergroup differences were assessed for
significance using non-parametric statistical tests, i.e., the
Mann–Whitney U and Kruskal–Wallis tests, followed
by pair-wise post hoc tests corrected for multiple
comparisons. The threshold of significance was
defined as p < 0.05.
Possible associations of sporadic ALS with levels of
pNfH, S100-β, cystatin C, and CHIT in CSF were
explored using multivariate logistic regression, with ad-
justment for age and sex as potential confounders. In
this regression, biomarker levels were treated as cat-
egorical variables by stratification into quartiles based
on the distributions observed in controls. The quartile
with the lowest biomarker levels served as the reference
group. Receiver operating curve (ROC) analysis was
used to calculate an optimal cut-off level to discriminate
patients with sporadic ALS from controls. Spearman
rank correlation was used to explore possible correla-
tions between demographic variables, disease duration,
ALSFRS-R and progression rate on one hand and bio-
marker levels on the other. Patients were divided into
various subgroups, and biomarker levels were compared
between them using the Van Elteren test.
Results
Demographic and clinical characteristics of patients and
controls are listed in Table 1. Most patients (33) had the
spinal-onset form of the disease. Among all patients, mean
rate of disease progression, in terms of ALSFRS-R score,
was 0.91/month. Twelve patients were defined as showing
rapid progression because their monthly rate of progres-
sion was >0.91. Among all patients, mean rate of decline,
again in terms of ALSFRS-R score, was 11.01/year, corre-
sponding to a mean rate of decline of 0.92/month. Ten pa-
tients were defined as showing rapid worsening because
Table 1 Demographic and clinical characteristics of patients with
sporadic amyotrophic lateral sclerosis and controls with non-ALS
neurological disorders
Characteristic ALS (n = 40) Controls
(n = 40)
Male, n (%) 26 (55) 24 (60)
Age, yr 52.08 ± 11.45 53.68 ± 11.93
Age at onset, yr 57.96 ± 10.96
Disease duration, mo 17.61 (2.77–50.43)
Site of onset (spinal/bulbar), n 33/7
ALSFRS-R score 38.32 (21–47)
Progression rate 0.91 (0.08–5.06)
Rapidly progressive (progression
rate > 0.91/month)/Slowly progressive
(progression rate≤ 0.91/month)
12/28
Annual decline of ALSFRS 11.01 (3.10–33.31)
Monthly decline of ALSFRS 0.92 (0.26–2.78)
Rapidly worsening 0.92/month)/ 10/16
Slowly worsening (monthly
decline of ALSFRS-R ≤0.92/month)
26/11/3
Survival/death/ lost to follow-up 26/11/3
Values shown are n, n (%), mean ± SD, or median (range)
ALSFRS-R, Amyotrophic Lateral Sclerosis Functional Scale - Revised
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their monthly rate of decline was >0.92. Eleven patients
died during follow-up, and three were lost to follow-up.
Levels of pNfH, CHIT, cystatin C, and S100-β in CSF
Patients with sporadic ALS showed significantly
higher levels of pNfH and CHIT in CSF than controls
did (P < 0.0001; Fig. 1a-b). Conversely, patients with
ALS showed a significantly lower level of cystatin C
(P = 0.0009; Fig. 1c). Patients and controls did not
differ significantly in levels of S100-β (Fig. 1d).
Associations of sporadic ALS with levels of pNfH, CHIT,
cystatin C, or S100-β
Multivariate logistic regression was used to explore pos-
sible associations of ALS status with levels of pNfH,
S100-β, cystatin C, or CHIT in CSF. The regression
model adjusted for age and sex as possible confounders.
Sporadic ALS was significantly associated with higher
levels of pNfH, higher levels of CHIT, and lower levels
of cystatin C. No significant correlation was identified
between disease status and levels of S100-β.
Using ROC analysis, we calculated an optimal pNfH
cut-off of 437 ng/L to discriminate patients with
sporadic ALS from controls. This cut-off showed a sensi-
tivity of 97.3 % and specificity of 83.8 %; the area under
the ROC curve (AUC) was 0.938 (95 % CI 0.884–0.991).
Using a CHIT cut-off of 1593.779 ng/L gave a sensitivity
of 83.8 %, specificity of 81.1 % and AUC of 0.854 (95 %
CI 0.768–0.940; Fig. 2). Simultaneously applying both
cut-offs gave a sensitivity of 83.8 %, specificity of 91.9 %
and AUC of 0.952 (95 % CI 0.909–0.994.
Associations of clinico-demographic characteristics with
levels of pNfH, CHIT, and cystatin C
Subgroups of patients with bulbar or spinal onset of
sporadic ALS were similar in terms of pNfH, CHIT,
and cystatin C levels. Levels of pNfH were signifi-
cantly higher in patients with rapidly progressing
disease than in those with slowly progressing disease
(P = 0.001), and they were higher in patients with
rapidly worsening disease than in those with slowly
worsening disease (P = 0.0143). Levels of CHIT and
cystatin C did not differ significantly between sub-
groups stratified by monthly rate of progression or
decline. No significant associations were observed be-
tween ALSFRS-R score or disease duration on one
hand and levels of the three biomarkers on the other
(Table 2).
Discussion
In this study, we found that levels of pNfH in CSF were






































































































CSF Cystatin C levels in SALS patients and controls.  CSF S100B levels in SALS patients and controls.
Fig. 1 Scatter plot of levels of pNfH, S100-β, cystatin C, and CHIT in CSF in patients with sporadic ALS and control patients with non-ALS
neurological disorders. *the difference is significant
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in controls with non-ALS neurological disorders. Similar
results have been reported in other populations [3, 4]. In
fact, Ganesalingam et al. reported 10-fold higher mean
levels of pNfH in CSF in patients with ALS [5]. A large
study of 455 patients reported significantly higher levels
of pNfH in patients than in controls [6]. Multivariate
regression of our data showed that sporadic ALS was as-
sociated with high levels of pNfH in CSF, even after
adjusting for potential confounding variables. This sug-
gests a possible role of pNfH in the pathogenesis of
ALS, and it is consistent with studies showing that
phosphorylation of NfH slows its axonal transport and
interaction with other cytoskeletal proteins, affecting the
course of ALS [7]. Higher levels of pNfH in the CSF of
patients with ALS may reflect higher content of axonal
proteins in motor neurons and greater extent of axonal
injury, leading to the release of large amounts of pNfH
into the extracellular space and ultimately into the CSF
[8]. A recent study investigated CSF of 455 patients for
pNfH, and it also reported that pNfH levels were signifi-
cant higher in ALS patients compared to the control
groups [6].
Building on this observed association between spor-
adic ALS and levels of pNfH, we examined whether this
Fig. 2 Receiver operating curve (ROC) analysis
Table 2 Comparison of levels of pNfH, CHIT, and cystatin C in cerebrospinal fluid between subgroups of patients with sporadic ALS
Subgroup pNfH (ng/L) P value CHIT (ng/L) P value cystatin C (ng/L) P value
Site of onset
Spinal 4676 (238–19002) 0.43 4457 (572–7945) 0.08 10330 (62–111466) 0.35
Bulbar 3022 (552–5265) 2886 (91–7945) 3065 (119–1113)
Progression rate
>0.91/month 5969 (996–19002) 0.001 3927 (572–7945) 0.85 6566 (62–105031) 0.80
≤0.91/month 1969 (238–5030) 3791 (91–7945) 12900 (62–111466)
Worsening rate
>0.92/month 6171 (1309–19002) 0.0143 4668 (598–7945) 0.67 5188 (78–32186) 0.83
≤0.92/month 2670 (238–13223) 4243 (572–7945) 15610 (62–111466)
ALS amyotrophic lateral sclerosis, CHIT chitotriosidase, pNfH phosphorylated neurofilament heavy chain
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biomarker shows diagnostic potential. Using a cut-off of
437 ng/L to discriminate between patients and controls
gave sensitivity of 97.3 % and specificity of 83.8 %. These
results are consistent with other studies reporting
relatively high sensitivity and specificity, although the
optimal cut-off values vary substantially. Using a cut-off
of 950 ng/L, Brettschneider et al. reported sensitivity of
71 % and specificity of 88 % [3]. Using a cut-off of
502 ng/L, Reijn et al. obtained sensitivity of 72 % and
specificity of 80 % [4]. Steinacker et al. reported 83 %
sensitivity and 77 % specificity with a cut-off of 560 ng/L
[6]. Ganesalingam et al. reported sensitivity of 87.7 %
and specificity of 93.7 % with a cut-off of 635 ng/L [9],
while the same laboratory obtained respective values of
90 % and 87 % using a cut-off of 1200 ng/L in a larger
patient sample [5]. This large variation in cut-off value
may reflect the relatively small size of study populations,
ethnic differences among the populations, and the
intrinsic heterogeneity of sporadic ALS. The large vari-
ation may also reflect differences among the ELISA kits
used. Given the strong evidence of diagnostic potential
for pNfH levels in CSF, future work is urgently needed
to develop and validate standard clinical biochemistry
procedures for assaying this biomarker [10].
While pNfH levels are associated with presence of
sporadic ALS, they do not appear to predict site of dis-
ease onset. In our study, levels were similar between
subgroups of patients with bulbar or spinal onset. This
is consistent with previous studies [3, 11].
We also investigated whether pNfH levels in CSF may
show prognostic potential. We found that these levels
did not correlate with clinical disability (ALSFRS-R
score) at the time of diagnosis, consistent with a previ-
ous study [3]. However, these levels were significantly
higher in our patients who suffered more rapid decline
in ALSFRS-R score. In addition, the levels were signifi-
cantly higher in patients with more rapidly progressive
disease based on the progression rate [12, 13]. This
echoes previous work associating elevated levels of pNfH
with faster progression of ALS [3]. This suggests that
pNfH levels may predict functional worsening in ALS. It
may be that more aggressive disease is associated with
increased, sustained cytoskeletal breakdown within
motor neurons, which would lead to greater leakage of
pNfH into CSF.
Our data also showed CHIT, an enzyme synthesized
by microglia or infiltrating macrophages, to be present
at significantly higher levels in CSF in patients with
sporadic ALS than in controls. This is consistent with
previous studies [1, 2]. Higher CHIT levels may reflect a
neuroinflammatory response triggered by microglia,
since CHIT is considered a marker of microglial activa-
tion in stroke [14] and, like pro-inflammatory cytokines,
an index of inflammation severity [15]. We further found
that CHIT levels can distinguish patients from controls
with sensitivity of 83.8 % and specificity of 81.1 %, giving
an acceptable AUC of 0.854. To our knowledge, this is
the first evidence that CHIT has diagnostic potential in
sporadic ALS. At the same time, we found similar CHIT
levels in subgroups of patients with rapidly or slowly
progressing disease, in contrast to a previous study [2].
This may reflect clinical heterogeneity among patients
with sporadic ALS.
We examined whether the combination of pNfH and
CHIT levels may provide greater diagnostic accuracy than
either biomarker alone. Using both gave a much higher
specificity than pNfH alone (91.9 % vs. 83.8 %), but a
lower sensitivity (83.8 % vs. 97.3 %). Our results suggest
that combining pNfH and CHIT improves diagnostic spe-
cificity without sacrificing too much sensitivity.
We found that levels of cystatin C in CSF were signifi-
cantly lower in patients with sporadic ALS than in
controls. While several studies have reported a similar
decrease in cystatin C levels in patients [16–19], analysis
of samples from six centers in Europe failed to detect
differences between patients and controls [20]. This
discrepancy may reflect well-known preanalytic artifacts
in assaying cystatin C [21]. It may also reflect complex
roles of cystatin C: this cysteine proteinase inhibitor has
been implicated in both neuronal degeneration and
neuronal repair. For example, Wilson et al. reported that
cystatin C levels increase when ALS remains stable or
progresses slowly, whereas levels decrease when disease
progresses rapidly [22]. However, our data failed to indi-
cate an association of cystatin C levels with disease
progression, duration, or severity. Moreover, cystatin C
levels could not distinguish patients from controls.
Future studies should examine in greater detail the
potentially complex role(s) of cystatin C in ALS.
We found no association between sporadic ALS and
levels of S100-β in CSF. This contrasts with several pre-
vious studies suggesting that this protein, which modu-
lates the activity of effector proteins or cells, is present
at higher levels in the CSF of patients with ALS [23–25].
Regardless of whether ALS involves changes in S100-β,
assaying this protein is unlikely to be helpful for differ-
ential diagnosis of the disease, since levels of the protein
have also been shown to change in other neurodegenera-
tive disorders.
The results from our study should be interpreted with
caution in light of at least three substantial limitations.
One is our small sample, and another is the cross-
sectional design. Future work should monitor biomarker
levels and disease onset and progression longitudinally.
Third, our assays were not independently verified by an
external laboratory.
Despite these limitations, the present study strengthens
the evidence base that pNfH and CHIT are
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neuropathological hallmarks of ALS. Levels of pNfH and
CHIT in CSF were significantly higher in patients than in
controls, while levels of cystatin C were significantly lower
in patients. In addition, pNfH levels in CSF correlated
with disease severity and progression, and they dis-
criminated patients from controls with high sensitivity
and specificity. These findings point to pNfH as per-
haps the single most promising candidate biomarker
for ALS. At the same time, combining pNfH with
CHIT may improve diagnostic accuracy. Given the
heterogeneity of ALS, our results highlight the need
for large longitudinal studies of patients with several
disease phenotypes in order to verify and compare
the ability of these biomarkers, alone and in combin-
ation, to differentiate ALS from related disorders.
Conclusions
Despite these limitations, the present study strengthens
the evidence base that pNfH and CHIT are neuropatho-
logical hallmarks of ALS. Levels of pNfH and CHIT in
CSF were significantly higher in patients than in con-
trols, while levels of cystatin C were significantly lower
in patients. In addition, pNfH levels in CSF correlated
with disease severity and progression, and they discrimi-
nated patients from controls with high sensitivity and
specificity. These findings point to pNfH as perhaps the
single most promising candidate biomarker for ALS. At
the same time, combining pNfH with CHIT may im-
prove diagnostic accuracy. Given the heterogeneity of
ALS, our results highlight the need for large longitudinal
studies of patients with several disease phenotypes in
order to verify and compare the ability of these bio-
markers, alone and in combination, to differentiate ALS
from related disorders.
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